When it comes to innovation and the marketing mix, some say the
healthcare industry lags behind. As a healthcare marketing solutions
company, we work feverishly to keep our finger on the pulse of innovation and
creative solutions for our clients. MedTera understands that innovation isn’t
spurred solely from looking inward in healthcare. We look outward to leaders
of marketing innovation from all industries. This is healthcare marketing in
the 21st century. We "deliver beyond the fold" by integrating dimensional
and digital solutions into multi-wave marketing campaigns that capture the
attention of your key targets to engage and elicit response. We assist in marketing your brand by turning medical facts into creative ideas.
OpenFDA was launched by the U.S. Food and Drug Administration in June 2014 as a way to create easy access to public health data, develop a new level of openness and accountability, educate the public and ensure the privacy and security of public FDA data. However, according to the FDA, the underlying goal of openFDA is to save lives.
The patient perspective is having an increasingly important role in the way pharmaceutical companies advertise their products. Making consumers feel involved in their own health and the drugs that they're taking has become key to connecting with patients and drawing their attention to a brand.
Grabbing the attention of target audiences and getting them to remember products are some of the biggest challenges for pharmaceutical marketers. With so many competitors advertising their drugs, how do marketers get consumers to notice their campaigns? It's all about patient engagement and building credibility. To accomplish this, many companies are turning to the art of storytelling as a way to make their ads more relatable and memorable for consumers.
Many experts in the pharmaceutical industry have predicted trends that could emerge in 2015. Everything from how pharma companies interact with patients to wearable devices play a major role in what the future looks like for the pharma industry. Many of these aspects are expected to change over the next few months.
Congress has announced a new proposal that would permit pharmaceutical companies to share with doctors, researchers and insurers what is considered off-label information about their drugs approved by the U.S. Food and Drug Administration.